Founded in 2005 and headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC specializes in the engineering of novel biologics to treat anemias, cancers and their debilitating comorbidities by leveraging the multi-faceted core attributes of PEGylation technology. Led by Dr. Abraham Abuchowski, the founding team includes the inventors of PEGylation, the most successful drug delivery technology in pharmaceutical history, which is now responsible for more than $30 billion in drug sales worldwide.  The company's lead product, SANGUINATE™, focuses on treating disorders caused by ischemia, hypoxia and/or hemolysis.  It is in clinical testing for the comorbidities of sickle cell disease and other anemia-related conditions with broader applications forecasted for the future.

Tarsadia’s investor group initially invested in Prolong in 2009 and has continued to support it as lead financial partner to achieve ongoing developmental milestones.